Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3795 (PT2385) in VHL-Associated ccRCC
NCT03108066Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2017
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PT-2385 in clear cell renal cell carcinoma (ccRCC) and von Hippel–Lindau disease (VHL), sponsored by Merck & Co. Primary endpoint: Overall Response Rate in VHL Disease-Associated ccRCC Tumors. Started Apr 2017; status: completed.
02
Drugs
PT-2385
03
Conditions
clear cell renal cell carcinoma (ccRCC)von Hippel–Lindau disease (VHL)
Beyond the preview
Go deeper on NCT03108066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03108066.